Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer

NCT06008925 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

43

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Gastric Cancer

Interventions

DRUG: Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))
DRUG: Nivolumab Injection

Sponsor

CNBG-Virogin Biotech (Shanghai) Ltd.